Abstract
Background The emergence of COVID-19 requires alternative treatments based on the reuse of drugs as a strategy to prevent the progression of the disease in patients infected with SARS-COV-2. The goal was to evaluate the use of ivermectin in mild stage outpatients to heal and / or reverse the progression of COVID-19 disease towards the development of moderate or severe stages.
Methods Cluster Assigned Clinical Trial (2:1) in outpatients, n = 234. The subjects were divided into experimental (EG: n = 110) and control groups (CG: n = 62). The EG received ivermectin orally 4 drops of 6 mg = 24 mg every 7 days for 4 weeks. All participants were diagnosed by positive RT-PCR for COVID-19 and were evaluated by clinical examination, at the beginning and the end of protocol. Data analyzed were applied the proportion, bivariate, and logical regression tests with level significance p < 0·05. This study was registered at ClinicalTrials.gov Identifier NCT04784481.
Findings Both groups were similar in age, sex, and comorbidities (EG: 56F, median age= 40·0, range: 18·0 - 75·0; CG: 34F, median age = 37·5, range: 18·0 - 71·0). A significant reduction in the symptom numbers was observed in the EG when the medical examination was performed from 5th to 9th days, after starting treatment (p = 0·0026). Although, medical examination from 10th to 14th day, showed a progressive reduction of the percentage symptom numbers, these were not significative in both groups. A higher proportion of medical release was observed in EG (98·2%) vs CG (87·1%) (p = 0·003). EG showed 8 times more chance of receiving medical release than CG (OR 7·99, 95% CI: 1·64 −38·97, p = 0·003). The treatment effect with ivermectin to obtain medical release was analyzed by the logistic regression model based in the following control variables: sex, age, and comorbidities. Then, the chance to obtain medical release was maintained in EG (OR 10·37, 95% CI: 2·05 - 52·04, p = 0·005).
Interpretation Treatment with ivermectin in outpatients with mild stage COVID-19 disease managed to slightly reduce the symptom numbers. Also, this treatment improved the clinical state to obtain medical release, even in the presence of comorbidities. The treatment with ivermectin could significantly prevent the evolution to serious stages since the EG did not present any patient with referral to critical hospitalization.
Clinical Trials registry number is NCT04784481
Funding Ministry of Public Health. Tucumán, Argentina.
Evidence before this study Currently there are no specific therapies approved for COVID-19 treatment by the FDA, that is why different repositionable drugs are being studied in clinical trials and compassionate use protocols based on in vitro activity. ivermectin is a broad spectrum antiparasitic agent that has been shown to have antiviral activity against a wide range of viruses. A study by Caly et al. (2020) suggested thatnuclear transport inhibitory activity of ivermectin may be effective against SARS-CoV-2. Since the publication of that work, numerous clinical trials were started to study ivermectin potential for COVID-19 treatment. At the end of March 2021, there were about 60 studies registered in https://www.clinicaltrials.gov, and 43 studies listened https://www.who.int/clinical-trials-registry-platform about the safety and effectiveness of ivermectin in COVID-19 patients, for treatment and prophylaxis. Most of these studies are from developing countries, which shows the need of emerging economies to find alternative therapies to contain the spread of the disease and the collapse of health systems.
Added value of this study We found that an early intervention with ivermectin has impacted on the score of symptoms related to COVID-19 in ambulatory patients, between the 5th and 9th day. The patients who received the treatment changed from score 2 to score 1 in the WHO ordinal scale. In any case, patients evolved to higher scores. Also the treatment increased the probability to obtain medical release, even in the presence of comorbidities.
Implications of all available evidence According to the COVID-19 Treatment Guidelines by the NIH, most trials have several limitations. It needs results from adequately powered and well-designed clinical trials to provide evidence-based guidance on the role of ivermectin in the treatment of COVID-19. However, our study shows overlaps in benefits with other authors, and taking together, these results are encouraging for further study about repurposing ivermectin for the treatment of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04784481
Clinical Protocols
Funding Statement
Ministery of Health, Tucuman, Argentina.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Board Status: Approved Approval Number: 054/2020 Board Name: Independent Ethical Comitee. Board Affiliation: ReNIS (National Register in Health Research) Argentina. Number 0032
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data Sharing Statement Data available:Yes Data types:Participant data with identifiers How to access data:E-mail request for data: mperal{at}fm.unt.edu.ar - Dr. Maria Peral de Bruno Who can access the data:Researchers whose proposed use of the data has been approved Types of analyses:for a specified purpose Mechanisms of data availability:with investigator support
